JAK2 and myeloproliferative neoplasm: Among both ET and PMF patients, JAK2‐V617F positive cases showed higher PD‐L1 mRNA expression in granulocytes compared to CALR‐mutated MPN patients (p < .005 and p < .01, respectively; Figure 1B).